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Abstract
Background: High accrual to clinical trials enables new treatment strategies to be tested rapidly, accurately and
with generalisability. Ethical standards also must be high so that participation is voluntary and informed. However,
this can be difficult to achieve in trials with complex designs and in those which are closely embedded in clinical
practice. Optimal recruitment requires a balance of both ethical and accrual considerations. In the context of a trial
of stratified treatments for children with acute lymphoblastic leukaemia (UKALL2003) we examined how
recruitment looked to an observer and how it felt to the parents, to identify how doctors’ communication could
promote or inhibit optimal recruitment.
Methods: We audio-recorded, transcribed and analysed routine doctor-patient consultations (n = 20) and
interviews between researchers and parents (n = 30 parents) across six UK treatment centres. Analysis was
informed by the constant comparative method. For consultation transcripts, analysis focussed on how doctors
presented the trial. We compared this with analysis of the interview transcripts which focussed on parents’
perceptions and understanding of the trial.
Results: Parents and doctors discussed the trial in most consultations, even those that did not involve a decision
about randomisation. Doctors used language allying them both with the trial and with the parent, indicating that
they were both an ‘investigator’ and a ‘clinician’. They presented the trial both as an empirical study with a
scientific imperative and also as offering personalisation of treatment for the child. Parents appeared to understand
that trial involvement was voluntary, that it was different from routine care and that they could withdraw from the
trial at any time. Some were confused about the significance of the MRD test and the personalisation of treatment.
Conclusions: Doctors communicated in ways that generally promoted optimal recruitment, indicating that trials
can be embedded into clinical practice. However, parents were unclear about some details of the trial’s rationale,
suggesting that recruitment to trials with complicated designs, such as those involving stratified treatments, might
need enhanced explanation.
Background
Clinical trials are the gold standard by which new treat-
ments can be reliably tested against current therapies in
an attempt to optimise treatment. Paediatric oncology
has a tradition of high accrual to trials, although there is
considerable variation between trials of treatments for
different types of cancer [1-3]. High accrual to clinical
trials in childhood cancer is crucial if improvements in
treatment are to be maintained, but it is important also
to ensure recruitment is conducted in a way that is
appropriate for both families and practitioners and is
ethically sound. High recruit m e n ti sn o t ,t h e r e f o r e ,t h e
ultimate goal, but rather it is “optimal recruitment”,
which takes into account that it is essential that families
are able to make informed decisions and to decide
themselves whether to enter their child into a trial or
not [4].
Certain elements of the way that recruitment is con-
ducted in such trials have been proposed to promote high
accrual [3]. These include: that the research question is
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that both parties are comfortable with the clinical and per-
sonal equipoise of the study (i.e., that they believe that
there is no clear evidence that one treatment is better than
another per se or for the individual child). Communication
between the doctor and decision maker (typically a parent)
about the trial has also been shown to be important [5],
ensuring, for example, that information about the trial is
personal, tailored and timely. It has been proposed that
the focus of the consultation in which a trial is discussed
should be coherent to parents [3,6]. If a parent believes
that a consultation’s purpose is to discuss specific results
or treatment they may perceive the discussion of a trial as
an unwelcome deviation. Throughout recruitment, parents
should feel that the doctor gives priority to their child’s
care over the scientific imperative of the trial and that if
trial continuation brought significant physical or emo-
tional cost, the doctor would withdraw the child.
It has been proposed that, before parents give consent
for their child to participate, they should be aware:
1) that the trial is different from routine clinical practice,
2) that the treatment is randomly allocated due to uncer-
tainty about which treatment is best, and 3) of the risks,
benefits and the right to withdraw from the trial [3,7].
Trial recruitment processes vary between specialities
and trials and each situation brings its own specific proce-
dural and ethical challenges. Particular challenges arise in
paediatrics linked to children’s vulnerability, and legal fra-
meworks that require parents, not patients, to provide
consent for entry to a trial [8]. Concerns have been voiced
about doctors recruiting patients for whom they have
direct clinical responsibility due to a conflict between
being both an investigator and the patient’s clinician
[9,10]. In paediatric oncology it is often the physician with
clinical responsibility for the child who approaches the
parents about participating in a trial and there is a strong
interwoven relationship between routine clinical care and
clinical trials. This has been proposed as advantageous for
accrual [11] but also as an ethical challenge [9], with evi-
dence in paediatric oncology that parents can struggle to
distinguish between treatment that is standard practice
and treatment that is part of a trial [12,13]. It has, there-
fore, been suggested that, in the context of a dependent
family-practitioner relationship, high rates of accrual are
gained at the expense of informed consent and voluntari-
ness [14].
We investigated how recruitment was conducted in the
context of a clinical trial of treatment for childhood leu-
kaemia by focussing on how physicians negotiated the
tensions between ensuring high accrual and maintaining
high ethical standards. The trial had a complex design
with two randomisation points and was investigating
treatment stratification. We examined the conduct of
recruitment from two perspectives: how recruitment
‘looked’ to the observer and also how it ‘felt’ to the par-
ent. By examining these two perspectives simultaneously
our aim was to see if transferable lessons could be learnt
regarding how to ensure ‘optimal’ recruitment to clinical
trials.
Methods
We studied routine consultations between doctors and
parents of children with acute lymphoblastic leukaemia
(ALL). We collected audio-recordings of these consulta-
tions, together with follow-up parent-researcher semi-
structured interviews, as part of a wider qualitative
study (RAPPORT). This study investigated clinical com-
munication and the parent-practitioner relationship in
the care of children with leukaemia with the aim of
informing clinical communication practice and training
of practitioners. We conducted this study during the
period when the UKALL2003 trial (Medical Research
Council/National Cancer Research Institute trial) was
open to recruitment in the UK. The UKALL2003 trial
was a prospective randomised trial investigating if treat-
ment allocation, determined by standardised disease
indicators (white cell count and age) plus a molecular
test of response to early treatment (minimal residual
disease: MRD) could increase survival and minimise
toxicity in children with ALL. The trial randomised chil-
dren at one of two points:
1) If a child was in clinical remission at 28 days of
treatment but the MRD showed high levels of residual
disease not visible under the microscope, randomisation
between the standard treatment (for those in clinical
remission) and a more intensive treatment (the intensity
of treatment usually given to children who are not in
clinical remission at day 28) was offered. This randomi-
sation point occurred approximately four weeks after
treatment had begun.
2) If a child was in clinical remission at 28 days, and
had low levels of MRD at 28 days and again at 11 weeks,
randomisation between standard treatment (according to
their clinical disease indicators) and reduced intensity
treatment was offered. This randomisation point
occurred approximately 12/13 weeks after treatment had
begun.
Doctors did not receive payment for recruiting to the
trial. Participants were registered in the trial at the time
they started treatment, but not all eligible registered par-
ticipants went on to accept randomisation. Since the
decision about entering randomisation is a key one, these
decisions were crucial to our investigation.
Participant recruitment
Participants were recruited to the RAPPORT study from
six UK principal treatment centres. Parents were initially
approached about RAPPORT by a member of clinical
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study with a RAPPORT researcher. Researchers
explained their independence from the clinical teams
and that all study information would be kept confiden-
tial. Parents who agreed to participate completed a writ-
ten consent form. Researchers informed parents that
they would re-contact them after the audio-recorded
consultation to arrange the interview. The study was
approved by a UK National Health Service Research
Ethics Committee (Ref. 06/MRE08/18).
Procedure
Sampled consultations included a range of consultations
varying from ones that took place immediately before
the first set of results that lead to randomisation point
1, to just before the second set of results which lead to
randomisation point 2. Parents were interviewed after
the audio-recorded consultation. To ensure exploration
of core topics, interviewers used a topic guide with
prompts about parents’ experiences of: communication,
consultations including the audiorecorded ones, rela-
tionships with staff, and the impact of the illness and
treatment on their child (see outline summary in Addi-
tional File 1). Trial recruitment was not a pre-planned
focus of the overall RAPPORT study or interview ques-
tioning. Therefore, discussion of these issues was usually
initiated by parents rather than interviewers, although
the open-ended and conversational nature of the inter-
views facilitated parents in introducing or expanding
discussion on topics that were important to them. Con-
sultations and interviews were digitally audio-recorded
and transcribed. Transcriptions were anonymised. Tran-
scription was verbatim, recording all major disfluencies,
emphases and pauses but were stylised in that punctua-
tion was added; for the consultations we also recorded
overlapping speech.
Analysis
The consultation and interview data were linked within
cases whereby interview data were considered alongside
each corresponding consultation. Analysis was interpre-
tative, but we also considered the subjective meaning of
the text to the parents and the doctors. The analysis pro-
cedure was informed by the constant comparative
approach[15]. The transcripts were analysed for indica-
tors of category relevant to the analytical aims and these
categories coded. Categories were both emergent, in that
they were grounded in the data, and confirmatory, in that
we looked for the presence of factors suggested in the
literature as important for optimal recruitment. Identifi-
cation of category and coding referred to the transcript
as a whole, as well as the proximal content of utterances.
Codes were compared looking for disparities and consis-
tencies according to: 1) the focus of the consultations
particularly whether randomisation was imminent or not,
2) the doctor and 3) the centre. Analyses were conducted
by LBD, discussed extensively with KG and BY, and
refined in light of these and further discussions with PS
and TE. All investigators read several complete tran-
scripts. In presenting our results we use extracts from
consultations and interviews to illustrate each core cate-
gory. These extracts are accompanied with anonymised
identification codes indicating centres (A-F) and numeric
codes for doctor (D) and parent/family (F). For all
extracts, square brackets containing three dots [...] indi-
cate short sections of omitted speech. Square brackets
containing text indicate explanation added during tran-
scribing or analysis and capitals were added by transcri-
bers to indicate words emphasised by speakers. While
original transcription recorded hesitation less than one
second, overlapping speech and disfluency, for ease
of reading we removed most of these markers from
presented data extracts.
Results
Participants
Seventy-one families of newly diagnosed children were
cared for during the period when the study was open at
the six centres (Figure 1). Of these, 53 families were
approached about RAPPORT, 39 consented and 32 had
consultations available. Because of the sensitivity of the
situation we did not enquire why parents declined parti-
cipation in RAPPORT, but those who volunteered rea-
sons mainly reported that they were too busy caring for
their child. The trial was discussed in 20 consultations
which were therefore included in the final analyses for
this paper alongside interviews with 30 parents
(17 mothers and 13 fathers). The mean lag time from
consultation to interview was 17 days (sd = 15 days).
Families were from all quintiles of the Townsend Depri-
vation Index [16] with four from the most and seven
from the least deprived quintiles. Children were aged
2 to 11 years, (mean = 5; sd = 3; mode 2 [5 children]).
Although participation in RAPPORT was open to any-
one, all the families entered in these analysis were white
British and had English as their first language. Reflecting
the complexity of the topics explored, most interviews
lasted over one hour and many lasted more than two.
How recruitment looked
Structure of the consultations
Consultations had different foci: some largely focussed
on test results that determined whether a child was
eligible for randomisation whilst others were routine
clinical visits (Table 1). As Figure 1 illustrates, 62% of
all consultations included some discussion about the
trial, including randomisation. However, only five
included a specific discussion of an imminent decision
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Page 4 of 11about consent for randomisation. In these five consulta-
tions, doctors gave parents the results of the MRD test
which ultimately determined whether the child was eli-
gible to be randomised for more intense treatment. In
the other 15 consultations doctors and parents discussed
future possible randomisation or the rationale for the
trial more generally.
A striking feature of consultations was that many were
structured in a similar way by doctors and across centres.
Doctors led the consultations: they initiated discussions
about the trial and the child’s clinical management.
Unless the consultation focussed on discussion of MRD
results, the doctor or parent typically began by summar-
ising the child’s progress to date, then the trial was dis-
cussed and finally attention returned to the child’s
progress and well-being. The discussion of the trial was
always embedded in the routine clinical ‘business’ of
these consultations. In consultations where MRD results
were the main clinical ‘business’ of the consultation the
doctor began by discussing these results. Two crucial
issues arise from the structure of the consultations.
Firstly, the focus of the consultation, as observed by us,
appeared to be the child and not the trial. Secondly, spe-
cific discussions around randomisation decisions
appeared at a point during the consultation which linked
the trial to the child’s clinical management. Doctors sum-
marised the treatment to date and then explained how
there was uncertainty about how best to proceed and
thus introduced why participation in the trial would be
an appropriate course of action to consider.
Doctors as clinicians and investigators; trials as treatment
and research
When discussing the trial, some individual doctors
switched between presenting themselves as the manager
of the clinical care of the child, who was allied with the
parents (clinician role), or as allied with the trial (investi-
gator role). In the clinician role, doctors sometimes
emphasised their independence from the trial. For exam-
ple, a doctor explained to a family how s/he had recom-
mended that another patient leave the trial because
“I think her best interest is, best interests is to be out.”
Referring to the trial, this doctor stated “this is NOT my
study” and emphasised “my job is to look after her [the
patient]” (D/D2). Doctors also used language which dis-
tanced them from the trial by drawing a contrast (shown
in bold) between the perspectives of the clinical team and
parents, and the ‘perspectives’ of the trial:
“But from our point of view from looking at it
under the microscope she is in remission,t h a t
means that she’s responded, that the leukaemia’s
responded, most of the cells have gone away. [..] But
the wh- point of the- this leukaemia study is really
to ask a further question that even though the
cells that we can see under the microscope have
gone away is there still evidence of any leukaemia
cells hiding that we can’t necessarily see?” (C/D4)
“[using the MRD test] they’re looking, a much,
much better test than we have been able to use
over the years [...] they’re looking to see if the leu-
kaemia is above a certain level” (A/D2)
However, sometimes doctors also allied themselves
with the trial, using pronouns which implied that they
were part of the trial team:
“So what we’re doing in the UK is we’re running a
trial.” (D/D4).
Personalisation of treatment and the scientific imperative
Trials such as UKALL2003 aim to create an evidence
base for stratifying treatment for children in the future
but treatments were not being personalised within the
trial. However, doctors sometimes presented the trial in
a way that could be interpreted as a personalisation of
treatment. For example,
“And the whole object of this study [trial] is to try
and make sure that we give each child the treatment
that they need rather than giving every child exactly
the same [treatment]” (C/D4).
Table 1 Foci of the consultations
Audio-recorded
consultations (n)
Consultations in which the child was, or could
be, eligible for randomisation
High risk MRD - discussion about randomisation to more intensive
treatment
5
Low risk MRD - discussion about possible future randomisation to less
intense treatment depending on future results
6
Already randomised - discussing new treatment 1
No results yet - discussion about possible future randomisation
depending on future results
3
Consultations in which the child was not
eligible for randomisation
MRD inconclusive 3
Moved to a more intensive treatment for clinical need 2
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answering a scientific question in the future, rather than
providing more personalised treatment for the individual
child in the trial:
“I’ve given you some test results with the under-
standing of what it means [...] and the way to gain
that understanding is by going through the study
and so hopefully in five years or so from now we’ll
KNOW what this means and know whether it’s [the
M R Dt e s tr e s u l t ]i m p o r t a n ta ta l la n dw h a tw e
should do about it” (B/D1).
Uncertainty, clinical equipoise and personal equipoise
For a trial to be deemed ethical there must be uncer-
tainty about whether one treatment is more beneficial
than the other. This is termed clinical equipoise. Most
doctors readily presented uncertainty about the meaning
of the MRD test results saying, for example, “no [...] we
don’t know what MRD means"(B/D1). They also showed
uncertainty about which of the different treatments
offered as part of the trial were most effective saying
they were “happy for children in my care to be rando-
mised” because “this is a new test” and “I’m happy to
do either[...] I er believe in both arms of it” (B/D1) and
“5 years from the beginning [of the trial] look back and
say [...] the patients who have more than one in ten
thousand [cells remaining after first block of treatment]
some of them were on C and some were on B [...] none of
them made any difference or C was [better] or B might
be better” (D/D2).
However, two doctors expressed more certainty about
the MRD test. These doctors still presented the equi-
poise about the treatment options but stated that it was
known that high risk MRD led to poorer outcomes. One
doctor quoted evidence about how remission rates
depended on MRD results:
“So 7 out of the 10 children in that group [group in
clinical remission with high risk MRD] will never
r e l a p s e[ . . . ] [ i n ] t h eo v e r a l lg r o u p[ g r o u pi nc l i n i c a l
remission without MRD test] we say that about 8
out of 10 children erm with childhood leukaemia
will never relapse (F/D2).
Another doctor described how the MRD test could
confirm that the child was a low risk patient:
“added on to that test erm is something called mini-
mal residual disease or MRD, which is that test
which can test for leukaemia cells erm much better
[...] we’re going to plan one again for 11 weeks of
treatment [...] If it confirms that he is [...] a low risk
patient erm we will offer him the possibility of
actually getting less treatment than just the stan-
dard"(C/D2).
In addition to clinical equipoise some doctors’ com-
munication suggested they were in equipoise about
treatments for that individual child (personal equipoise).
For example, a doctor explained that s/he was happy to
deliver “either arm of treatment to [name of child]” and
“if I wasn’tI ’d be giving you the one that I thought was
better” (D/D1).
How recruitment felt to the parents
Researchers did not specifically ask parents about recruit-
ment to the trial during their follow up interviews so it
was they, rather than the researcher, who initiated all dis-
cussions about the trial as part of the RAPPORT inter-
view. It also meant that not all of the interviews
contained reference to the trial. When parents did dis-
cuss the trial their accounts were generally neutral. Par-
ents expressed very little negativity about the trial and
the negative comments they did make mostly concerned
the trial’sp r o c e d u r e ss u c ha sh a v i n gt om a k eav e r y
quick decision about randomisation, and being given
information about a trial immediately after diagnosis. We
found no evidence that the trial per se was viewed nega-
tively by the parents, although one did express dissatis-
faction with randomisation, which we will discuss later.
Parents appeared to understand equipoise, voluntariness
and randomisation
Parents appeared to understand that the trial was being
conducted because it was uncertain which of two treat-
ments would be most beneficial for patients like their
child (clinical equipoise). One father explained how the
evidence was not available to support his “gut reaction”
to “give him more chemotherapy” and that the doctor
“said we don’t understand the full implications of [the
MRD result]” (B/F2). A mother put it very succinctly:
“that’s the thing with the randomisations they don’th a v e
the figures at the moment to say well yes this regime
does work better than this regime” (D/F8).
However some parents had a preference for higher
intensity treatment, despite the information that they
had been given about the equipoise of the treatment
arms. In explaining why she had consented to randomi-
sation, one mother spoke of how, if her son died and
she had not accepted randomisation (and so her son
had not a chance of getting a higher intensity of treat-
ment), then she might feel she had not done everything
she could to improve his chances of survival:
“If there was a hope that he would get better treat-
ment then at least we felt like we’dd o n ee v e r y t h i n g
that we could [...] if the worst did happen if we’d
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I would have always thought what if we’dh a v ed o n e
regimen C, would it have made a difference and I
think we needed to know that we’d done everything
we possibly could” (B/F2).
This mother indicated a preference not to have lower
intensity treatment, saying that it would be “very diffi-
cult for me to say, yes, he could just have one [intensive
block]” (B/F2). A father, who accepted randomisation,
commented on his own difficulties in accepting that
there was equipoise “in the back of my mind I can’tl e t
go of the thought that two intensive periods is better
than one” (E/F1).
Parents indicated that they understood that the deci-
sion to enter their child in the trial was theirs emphasis-
ing how the doctor “stayed with me for about a good
half hour[...] giving me as much information as I wanted
before making the decision of whether to randomise or
not” (F/F2). They also described how doctors told them
that they could withdraw their child from the trial: “of
course we were told from day one that we could always
pull out of the trial” (C/F5) a n dt h a tt h i sw o u l db e
“without any repercussion whatsoever” (D/F3).
Where parents discussed randomisation they indicated
that they understood that randomisation was done by
computer: “It’s a bit strange cos it was, like, the compu-
ter was making the decision for you you know about
your child’s treatment and it wasn’t like us making the
decision or the consultant making a decision.” (D/F8)
and that it meant treatment was allocated by chance:
“because we’re in a trial, er, as far as I can gather, when
you get to a certain point it’s like pot luck, you get A or
B.” (F/F3). Although some parents had preferences
about treatment arms, as discussed earlier, only one
indicated displeasure that randomisation was the
method for treatment allocation:
“the computer makes the decision [...] and I just
think, they give you all this information and then, you
know, randomisation is just purely you’re picked at
random, it’s a lottery. It’s er, yeah, I think they should
have certain criteria, that maybe if you fit these speci-
fic criterias, or if you have a daughter that’sf i f t e e n
years of age, or twelve years or whatever, a reason for
it, or a reason for you not going on it would probably
be better rather than just saying ‘oh well, the compu-
ter picks and that’s it.’” (F/F5).
This parent appeared to believe that the treatment was
not rationally designed and that his child was receiving a
random treatment, rather than one that was rationally
designed but allocated at random. His concerns about
randomisation may have been linked to this belief.
Parents understood the purpose of the trial
Many parents showed that they clearly understood that
the trial was trying to balance the potential improve-
ments in survival with the greater risks of serious side-
effects from having more intensive treatment:
“we were slightly disappointed that [...] he got regi-
men A but of course the flip side of the coin is if he
gets away with it and he avoids a much more toxic
you know regimen then fantastic” (B/F2)
“he [the doctor] was saying, you know “you’ve got to
balance out the low risk here to the high intensity
here”. Does that balance out? And with her having
the [name of serious infection], um, do we really
want to put her at risk from being susceptible to
those sort of things again when, maybe, she doesn’t
really - in the bracket that she’si n ,w h e r ei ti sa
85%, 95% cure rate - do we need to put her in that
thing.” (F/F5).
Only five of the 30 parents commented on the scienti-
fic imperative of the trial, that its aim was to improve
treatments in the future, rather than improve treatments
for their child. Four of these expressed positive feelings
about helping families in other situations, for example:
“at every opportunity that we’re able to give some-
thing back in terms of information or supporting
them in some way we will do it. Um, this is [...] this
is such a massive ordeal that anything we can do to
make it easier for someone else we will do.” (E/F1).
H o w e v e r ,o n ef a t h e r-f r o mt h eo n l yf a m i l yi no u r
sample who discussed the trial in the recorded consulta-
tion and declined the randomisation - explained that
although he knew the trial “can help other children in
the future” he felt that “we’ve got to look after our child
[...] and we didn’t want [...] just don’t want her to suffer
any more” (D/F14). This father was clearly indicating
that he understood the scientific imperative of the trial
and was declining to participate.
Parents had some subtle misunderstandings about the trial
The clinical significance of the standard bone marrow
tests is well understood but, since the trial was investi-
gating the stratification of treatment on the basis of
MRD results, understanding the significance of the
MRD test was part of the trial’s rationale. However,
some parents believed that the MRD test was equivalent
to the standard bone marrow test in terms of the cer-
tainty about its prognostic meaning and its implications
for intensity of treatment. For example, one mother who
was told that her child was in clinical remission and was
subsequently given low risk MRD results explained how
prior to receiving the MRD results she had believed that
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he wouldn’tb ei nr e m i s s i o n ! " ( A / F 3 ) .I ts e e m e ds h ew a s
unclear that the basis of the MRD test is to find evi-
dence of disease that is not visible down the microscope.
Analysis of the consultation linked to this interview
indicated that, at the start of this consultation, the doc-
tor was aware of the bone marrow results, but not the
MRD results. Reflecting this, discussion focussed on the
bone marrow result with the doctor emphasising how it
indicated that the child had responded well to treat-
ment. About 9 minutes into the consultation the doctor
obtained the MRD result. Seeing that it was low risk he
explained that the result “just reinforces that we think
he’s having a good response to the treatment” (A/D2).
However, the doctor also went on to explain how
the MRD was a way of detecting if there were any leu-
kaemia cells left that could not be seen down the
microscope.
Another parent believed that the MRD test, taken
early in treatment, indicated a high risk of recurrence:
“When we had the result of the erm the MRD when
she had her last bone marrow and it indicated that
she was high risk of recurrence, that, that was quite
devastating again.” (C/F5).
At the time the trial was conducted there were strong
indications that the MRD was associated with higher
risk of recurrence. Nevertheless, as we explain above,
investigating the significance of the MRD test was part
of the trial’s rationale. The trial aimed to provide experi-
mental evidence of the relationship between the MRD
results and clinical recurrence, in the context of the spe-
cific treatment regimens. However, this mother seemed
to believe the MRD test provided incontrovertible evi-
dence that her child had a high risk of recurrence,
whereas the MRD, if the relationship was proven, would
indicate a higher risk of recurrence.
“It was almost like being told, as I said to [name of
doctor] that she had leukaemia [...] because it almost
we’r ed o i n gO Ka n dt h e n ,y o uk n o w ,w eh a v et h i s
high risk of recurrence.” (C/F5).
Finally, one mother indicated that because the “MRD
results came back as higher risk, she was randomised to
regimen C rather than stay on regimen A”.S h ea d d e d
that she was happy with this treatment allocation
because “the treatment’s going to step up a bit hopefully
to [...] get the leukaemia under control” (F/F2).S h e
believed that her child was receiving more intense treat-
m e n ta sad i r e c tr e s u l to ft h eM R Dr e s u l ta n d ,i nt h i s
sense, that the trial was offering personalisation of treat-
ment for her child rather than creating an evidence base
for stratified treatment in the future. She therefore
appeared to be confused about the rationale for the ran-
domisation in this part of the trial, which was to investi-
gate whether more therapy would improve outcome for
a child with a higher risk MRD result.
In the sampled consultations for these two families,
both doctors had expressed certainty about the prognos-
tic value of the MRD test. In the consultation with
family C/F5, the doctor stated that it was known that
high risk MRD was linked to higher recurrence rates
and explained that the trial’s purpose was to examine
whether altering treatment would improve outcome. In
family F/F2’s consultation, the doctor also presented
certainty, stating that a low risk MRD would increase
the future chances of staying disease free and adding
that the result “pushes into, way into, the [...] 90 per-
cents” (F/D3). However, neither doctor explicitly stated
that the impact of more intense treatment was certain,
nor did F/F2’s doctor make any statements that implied
the trial offered a way of personalising treatment for a
child.
Discussion
In explaining the trial, doctors were subtly, and some-
times implicitly, stressing their dual role and the inte-
gration of good clinical care with a clinical trial. Some
researchers have called for greater integration of clinical
care and research in order to improve accrual [11], but
others have voiced concerns about the ethics of doctors
recruiting patients for whom they have clinical responsi-
bility [9,17-19]. Because the motivation of the investiga-
tor (to answer an empirical question) and the clinician
(to manage the clinical care of the child) are different,
concerns have revolved around the potential for doctors
to unduly influence parental consent when recruiting
their own patients [9,19]. It has therefore been suggested
that doctors should declare their dual roles [19]. Doctors
were not required to overtly declare their dual roles in
this trial. However, by using language that sometimes
allied themselves with the trial and sometimes with the
parents, doctors were imparting information to parents
about their dual role, albeit in a subtle way.
The trial discussions were embedded within the con-
sultations and introduced at a time that seemed to link
the trial with the child’s clinical management. We argue
that this served to prioritise the clinical function of the
consultation to ensure that the child received the care s/
he needs, whilst allowing doctors to introduce the topic
of the trial without disrupting this crucial, primary
focus. Having the child’s clinical management as the
focus of the consultation had two implications. First it
signified that the trial was answering an important ques-
tion, which previous research has shown is important in
trial recruitment [3]. Second, it meant that there was no
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previously proposed as important in maintaining parent
and doctor comfort during trial discussions [3,6].
Of the sampled consultations, 62% had some discus-
sion of the trial. This indicated that doctors were main-
taining a regular dialogue about the trial and preparing
parents for future decisions, rather than only discussing
the trial at decision points. This might normalise being
part of a trial and also avoid parents being overwhelmed
with new concepts at emotionally difficult times. Our
finding that the trial was discussed at so many consulta-
tions supports the proposition that studying communi-
cation in trials by using just a single, a priori identified
consultation is likely to overlook these processes [20].
Not all parents initiated discussion of trial participa-
tion in their interviews and most of those who did
appeared to understand crucial aspects of the trial, parti-
cularly randomisation and the separation of clinical care
and trial participation. Thus parents either understood
the rationale/scientific question and that taking part was
their decision or they chose not to mention it. Parents
did not comment about the dual role of the doctors.
However, a few parents seemed confused about the
prognostic significance of the MRD test. In addition,
while this particular trial was creating an evidence base
about the stratification of treatment in the future, some
parents believed that their child’st r e a t m e n tw a sb e i n g
personalised as part of the trial. Indeed, some doctors
appeared to present the trial in this way. Where parents
believed in the prognostic certainty of the MRD test, we
have seen that, in the sampled consultations, doctors
had presented the MRD test with certainty. In contrast
to the confusion about the personalisation of treatment,
one father seemed to be concerned that randomisation
meant his child was receiving random treatment, rather
than random allocation of treatment. Parents did not,
however, express distress about being invited to partici-
pate in a trial or negative views about the overall pro-
cess of trial recruitment, but some did have concerns
about the timing of the approach.
We studied a trial in a specialty with traditionally high
accrual rates and which involved delayed randomisation,
allowing us to study deliberations about randomisation
as well as trial entry per se. Crucially, we considered two
complementary data streams: observation of the consul-
tations and interviews with the parents. This allowed us
to study how doctors presented trial participation, and
how the parents understood these discussions and
perceived the trial. We looked at trial discussions in a
variety of consultations, not just in those in which ran-
domisation decisions were imminent. The variety of
consultations was important since there is increasing
evidence that understanding the broader context and
experience of recruitment is important in understanding
the role that communication plays [20]. The way these
data were collected is crucial in understanding their sig-
nificance. The doctors and parents were taking part in a
wider study about general communication in the care of
children with leukaemia, rather than one specifically
focussed on communication about trial recruitment. We
believe that this avoided their responses being shaped by
how this study was framed and adds to the trustworthi-
ness of our findings. It is particularly noteworthy that
parents, in unprompted situation of their interviews, did
not harbour generally negative thoughts about being
approached to participate, the trial processes or their
own decision making.
Studies of recruitment to trials suffer from the likeli-
hood that people who do not want to take part in trials
often do not want to take part in other research. This
study is no different. Out of 71 families whose child was
cared for at the six centres during our recruitment per-
iod, most if not all of who were likely to have registered
for the UKALL2003 trial, only 32 had consultations
recorded. Of these, 12 were ineligible to be included in
these analyses because they did not involve a discussion
of the trial. Our final sample comprised only white Brit-
ish participants whose first language was English. This
may limit the transferability of the findings. Also, this
was a late phase trial involving stratification of treat-
ment protocols that were already very successful. Ran-
domisation might not, therefore, be as difficult a
decision as in trials where there is a greater uncertainty
regarding the outcomes of the different treatment arms
[21]. The leukaemia community has seen remarkable
improvements in treatments in recent decades, high
rates of trial accrual and acceptance of randomisation, a
culture of trial involvement among clinical staff and an
organisational infrastructure which facilitates trials
[22,23]. Our observations might not transfer to trials of
treatments in other clinical specialties with different his-
tories, cultural norms and organisation.
Lessons that could be learnt
This study compared how trial discussions looked to an
observer and how they felt to the parents of the children
being recruited. Our aim was to identify features of discus-
sions that could promote or inhibit optimal recruitment.
Trials can be embedded but caution is needed
The UKALL2003 trial was embedded in clinical practice.
It was discussed across many different consultations,
introduced at a time that seemed appropriate to clinical
c a r ea n db yt h ec h i l d ’s consulting physician. A similar,
highly integrated, approach has been recently proposed
to be a “method for conducting large trials at a low
cost” [11]. It might be feared, however, that such condi-
tions would promote high accrual at the expense of
voluntariness but we have not found evidence of this.
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standing of the trial, its separation from routine clinical
care and their right to choose to participate or not. The
only caveats was that there was some confusion among
parents between the creation of an evidence base for the
stratification of medicines and the personalisation of
treatment for their child and about the experimental
nature of the MRD test. Additionally, one father had
misunderstood random allocation as random treatment.
Our results show that these difficulties might have been
linked to the overall complexity of the trial itself and
how doctors explained the stratified medicine aspect of
the trial. Stratified medicine trials are complex, difficult
for doctors to explain, difficult for parents to understand
and therefore some confusion is perhaps understand-
able. Guidelines for doctors on how to explain such
trials may be useful. For stratified trials that run for sev-
eral years, such guidance could be supplemented by
updates on important evidence regarding the status of
the tests on which the stratification is based. More gen-
erally doctors might also consider exploring parents’
understanding using sensitive open questions that
enable parents to voice their views on key aspects of the
trial, before eliciting their decision about randomisation.
Doctors can display dual role, equipoise and uncertainty
Doctors in this study displayed two roles: clinician and
investigator. At times, they allied themselves with the
trial and presented the scientific rationale for the study.
At other times they allied themselves with the parents,
discussing whether the randomisation was right for the
child. We propose that the presentation of these roles
created a transparency about the doctors’ reasons for
involving themselves in research: to reduce treatment
uncertainty whilst ensuring that children in their care
receive the best treatments. Arguably, doctors’ presenta-
tion conveyed their goals to parents, which in turn
might foster trust. Doctors also showed parents the
logic that underpinned their request to enter the child
into the trial, i.e., in the absence of evidence about
which course of treatment is best it is justifiable to allo-
cate treatment by chance. Perhaps a more explicit
method for declaring dual roles at the time of trial
recruitment [19] would assist in creating transparency
and in fostering trust throughout the process of clinical
trial participation.
Trial design might assist optimal recruitment
This trial involved delayed randomisation. This might
assist parents in distinguishing between clinical care,
trials and other forms of medical research. It gives more
time for tailored and timely dissemination of trial infor-
mation, rationale and processes. Previous research has
shown that people report the advancement of science as
being an important driver in agreeing to take part in
trials [24-26]. However, discussing such scientific
rationales for trials might disrupt the focus of consulta-
tions about the child’s treatment and therefore discou-
rage trial participation. The delayed randomisation
element of this trial gave doctors opportunities to dis-
cuss the scientific imperatives and the science of trials
well before they discussed randomisation. Parents there-
fore had a chance to absorb information about the trial’s
scientific rationale separately from making the difficult
decision about randomisation of their own child.
Conclusions
A balance of ethical recruitment and high accrual is
necessary for optimal recruitment to clinical trials. Study-
ing communication about a trial in the light of two quali-
tative data streams has enabled us to consider how
communication might assist optimal accrual. Doctors
presented their dual role subtly and most parents under-
stood randomisation, voluntariness and the scientific
imperative of the trial. However, some parents were con-
fused about the purpose of this trial and the experimental
status of the MRD test. This might reflect the complexity
of this particular trial. Our findings support the embed-
ding of trials in clinical practice but we would urge
improved explanation in trials of stratified medicines to
avoid confusion about personalisation of treatment.
Additional material
Additional file 1: Topic Guide - Summary Version. Outline summary
of parent interview topic guide.
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